An observational study in Psoriatic Arthritis, sponsored by AbbVie. Recruiting at 132 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by AbbVie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.
Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 6th largest by planned enrollment of the 22 observational ones that give a count, is one of 2 that started in 2025, is one of 22 observational ones, and was the 33rd registered.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Czechia and 3 more countries
Ages 18+
AbbVie · Sites in United States, Australia, Canada and 6 more countries
Ages 5–17
AbbVie · Sites in United States
Women only
By country, each count listing its studies:
Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 280 across 244 observational studies indexed under Arthritis, Psoriatic.
Median enrollment 246 across the 11 interventional studies, 474 across the 22 observational. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Arthritis, Psoriatic by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice.
Risankizumab is an approved drug for the treatment of psoriatic arthritis. The study will not be conducted in the United States, however it will be conducted in approximately 15 countries and include at least 900 and up to 1200 participants with a 2 to1 ratio of participant allocation between participants receiving risankizumab and participants receiving other advanced therapeutic agents.
The therapy is prescribed in the usual manner in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population, and indication. All study visits will occur during routine clinical practice and participants will be followed for 24 months.
There is expected to be no additional burden for participants in this study.
Participants that currently are treated with Risankizumab or other advanced treatment options for the management of active psoriatic arthritis in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive bDMARDs as prescribed by their physician according to local label.
Participants will receive risankizumab as prescribed by their physician according to local label.
Number of participants that show persistence in treatment until 24 months
Persistence over 24 months, defined as a participant who starts PsA treatment and is still on the same therapy until 24 months.
Time frame: 24 Months
Not enrolling at this site — choose another above.
Showing the first 100 of 132 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.
Of 52 industry-sponsored observational studies under Arthritis, Psoriatic, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 48 months is close to that.
Counting every sponsor, half of 129 studies reached it within 47 months; a quarter within 28 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.